Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...

(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...

Diabetes is one of the most common conditions in the world and is associated with a broad range of adverse effects in multiple organ systems. Roughly half of all patients with diabetes will develop a ...

CIDP is a treatable condition that affects the peripheral nervous system. IVIG, plasma exchange, and corticosteroid therapy are the first-line treatment options, but a newer medication for adults has ...

Polyneuropathy occurs when multiple peripheral nerves malfunction throughout the body. Neuropathy is a common complication of type 2 diabetes mellitus (T2DM). Polyneuropathy occurs when there is ...

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...

Please provide your email address to receive an email when new articles are posted on . Reasons for misdiagnosis or delayed diagnosis for CIDP are complex and include multiple factors. The FDA ...

The US Food and Drug Administration (FDA) has approved the combination of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) for treatment of adults with chronic inflammatory ...

Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced ...

WAYNE, Pennsylvania (WPVI) -- One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get back on their feet. A great place to see their ...

CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...